XenoPort to Present at the RBC Capital Markets’ Global Healthcare Conference
2014 RBC Capital Markets' Global Healthcare Conference
SANTA CLARA, Calif. -- February 18, 2014
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via
the World Wide Web to its presentation at the RBC Capital Markets’ Global
Healthcare Conference. The live presentation will occur at 11:35 a.m. Pacific
Time (2:35 p.m. Eastern Time) on Tuesday, February 25, 2014. A replay of the
presentation will also be available.
To access the live presentation via the Web, please go to www.XenoPort.com.
Please connect to the Web site at least 15 minutes prior to the live
presentation to ensure adequate time for any software downloads that may be
necessary to listen to the Webcast.
A replay of the Webcast can be accessed for a minimum of one month and will be
available approximately 24 hours after the live presentation.
XenoPort, Inc. is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates for
the potential treatment of neurological disorders. XenoPort is currently
commercializing HORIZANT^® (gabapentin enacarbil) Extended-Release Tablets in
the United States and developing its novel fumaric acid ester product
candidate, XP23829, as a potential treatment for psoriasis and/or relapsing
forms of multiple sclerosis. REGNITE^® (gabapentin enacarbil) Extended-Release
Tablets is being marketed in Japan by Astellas Pharma Inc. XenoPort's pipeline
of product candidates also includes potential treatments for patients with
spasticity related to spinal cord injury and Parkinson's disease. To learn
more about XenoPort, please visit the Web site at www.XenoPort.com.
HORIZANT, REGNITE and XENOPORT are registered trademarks of XenoPort, Inc.
Jackie Cossmon, 408-616-7220
Press spacebar to pause and continue. Press esc to stop.